This online program is designed to provide pharmacists with the opportunity to learn more about the provision of evidence-based medication abortion care, as well as the current and future roles for pharmacists.
At the completion of this knowledge-based educational activity, pharmacists will be able to:
- Describe the current climate of access to abortion services in the United States.
- Review the mechanisms, indications, safety, and effectiveness of mifepristone-based regimens for medication abortion.
- List patient counseling points on medication use for medication abortion.
- Explain the effects of the US FDA REMS requirement that prohibits pharmacy dispensing of mifepristone on access to medication abortion.
- Discuss current and future pharmacist roles in the delivery of medication abortion services.
This home-study activity was initially released on August 1, 2020 and expires on July 31, 2023. There is no charge to participate, complements of ANSIRH, and it has received no commercial support.
To receive credit participants must view the entire one-hour video, complete the pre- and post-activity quizzes, and evaluate the content. For pharmacists, credit will be available through CPE Monitor electronically 2-4 weeks after participation. Your NAPB eProfileID and birthdate must be provided to receive credit. Non-pharmacists can download and print a certificate of participation at the conclusion of the activity.
PRESENTERS
Brooke Griffin, PharmD, BCACP
Professor of Pharmacy Practice and Vice Chair for Clinical Services
Midwestern University Chicago College of Pharmacy
Chicago, Illinois
Consultant, Birth Control Pharmacist
Daniel Grossman, MD, FACOG
Professor of Clinical Obstetrics, Gynecology & Reproductive Sciences
University of California, San Francisco
San Francisco, California
Sally Rafie, PharmD, BCPS, APh, NCMP, FCCP
Pharmacist Specialist UC San Diego Health
San Diego, California
Founder, Birth Control Pharmacist
DISCLOSURE
This UCSF CPE educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.
This activity has been reviewed and approved in accordance with UCSF CPE accreditation policies and the ACPE Standards for Commercial Support. Office of CME staff, planners, reviewers, and all others in control of content of this particular activity not listed below have disclosed no relevant financial relationships.
Sally Rafie, PharmD, is a clinical advisory board member for Afaxys, Inc., a speaker for TherapeuticsMD, and a consultant for GenBioPro. Conflicts of interest have been reviewed and resolved according to the Standards for Commercial Support.
ACCREDITATION
The University of California, San Francisco, School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This activity is approved for 1 contact hour under the ACPE University Activity Number 0005-0000-20-005-H04-P.
